Silo Pharma announced that CEO Eric Weisblum will present at the H.C. Wainwright 25th Annual Global Investment Conference to be held September 9-11, 2024. The in-person and virtual venue for the event is the Lotte New York Palace Hotel in New York City located at 455 Madison Avenue. Virtual participation will be staged simultaneously with company presentations scheduled as live feed or available on-demand. During his presentation, Mr. Weisblum will provide an update on the Company’s lead program, SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder. The next milestone for this PTSD drug program will be the GLP study data and the submission of an investigational new drug application to the U.S. Food and Drug Administration following studies currently in progress. Mr. Weisblum will also discuss the Company’s novel IP-protected technologies, assets, and additional investment highlights.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SILO:
- Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference
- Silo Pharma Announces Closing of $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
- Silo Pharma to sell 763,638 shares at $2.75 in registered direct offering
- Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
- Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15